October 19, 2020 -- Anti-infective therapies firm Aridis Pharmaceuticals has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
The company tested its candidate, AR-711, in a preclinical study on Syrian hamsters infected with SARS-CoV-2. The infected hamsters received a single exposure of inhaled AR-711 liquid aerosols, which eliminated detectable viral loads at all dose levels tested, including just 0.03 mg/kg, according to Aridis.
The therapeutic worked at lower doses than injected COVID-19 antibodies, the company noted. Aridis said the candidate's potency may be a result of its direct delivery to the lungs.
Aridis used a proprietary formula to stabilize the candidate and allow for delivery with a commercial nebulizer. This format could allow for wide-scale use in a variety of nonhospital settings, the company noted.
Aridis discovered the antibody from convalescent plasma in patients with COVID-19 and engineered it to last up to 12 months in blood, according to the company. It works by targeting the receptor-binding domain region in the novel coronavirus and emerging variants.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
